Development of a DNA-liposome complex for gene delivery applications

Rasoulianboroujeni, Morteza; Kupgan, Grit; Moghadam, Farzaneh; Tahriri, Mohammadreza; Boughdachi, Asma; Khoshkenar, Payam; Ambrose, Jessi; Kiaie, Nasim; Vashaee, Daryoosh; Ramsey, Joshua D.; Tayebi, Lobat

doi:10.1016/j.msec.2017.02.012

Cited by 47 publications

(29 citation statements)

References 73 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposomes offer several unique properties such as good biocompatibility, low toxicity, targeted drug delivery, and good biodegradability, etc. [114,115]. Due to the aforementioned properties, macromolecules such as antibodies, peptides, and polymers are used to modify their surfaces in order to enhance the blood circulation and for brain-specific delivery [114,115].…”

Section: Emulsionsmentioning

confidence: 99%

See 1 more Smart Citation

Chitosan-Based Nanocarriers for Nose to Brain Delivery

Aderibigbe

Naki

2019

Applied Sciences

View full text Add to dashboard Cite

In the treatment of brain diseases, most potent drugs that have been developed exhibit poor therapeutic outcomes resulting from the inability of a therapeutic amount of the drug to reach the brain. These drugs do not exhibit targeted drug delivery mechanisms, resulting in a high concentration of the drugs in vital organs leading to drug toxicity. Chitosan (CS) is a natural-based polymer. It has unique properties such as good biodegradability, biocompatibility, mucoadhesive properties, and it has been approved for biomedical applications. It has been used to develop nanocarriers for brain targeting via intranasal administration. Nanocarriers such as nanoparticles, in situ gels, nanoemulsions, and liposomes have been developed. In vitro and in vivo studies revealed that these nanocarriers exhibited enhanced drug uptake to the brain with reduced side effects resulting from the prolonged contact time of the nanocarriers with the nasal mucosa, the surface charge of the nanocarriers, the nano size of the nanocarriers, and their capability to stretch the tight junctions within the nasal mucosa. The aforementioned unique properties make chitosan a potential material for the development of nanocarriers for targeted drug delivery to the brain. This review will focus on chitosan-based carriers for brain targeting.

show abstract

Section: Emulsionsmentioning

confidence: 99%

“…[114,115]. Due to the aforementioned properties, macromolecules such as antibodies, peptides, and polymers are used to modify their surfaces in order to enhance the blood circulation and for brain-specific delivery [114,115]. Liposomes have been developed for brain targeting (Table 4).…”

Section: Emulsionsmentioning

confidence: 99%

Chitosan-Based Nanocarriers for Nose to Brain Delivery

Aderibigbe

Naki

2019

Applied Sciences

View full text Add to dashboard Cite

show abstract

“…The two DNA fragments were cloned into a pMIR-REPORT luciferase reporter plasmid and the mutated 3'-UTR seed sequence was used as the control. The plasmids containing 3'-UTR and mutated 3'-UTR sequences were transfected into 293T cells using the liposome method (20). miR-17 mimics (Hanheng Biotechnology) were transfected and cultured at 37˚C for 24 h, then cells from each group were lysed and fluorescence was measured with a GloMax 20/20 luminometer (Promega Corporation) using Renilla luciferase as the internal standard.…”

Section: Screening Of Pten Overexpression Cellsmentioning

confidence: 99%

MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the current study was to evaluate the expression of microRNA (miR)-17 in the endometrial tissues of patients with adenomyosis (AM) and determine its biological function in the occurrence and development of the disease. A total of 45 fresh endometrial tissues of AM patients and 32 normal endometrial tissues were collected from healthy controls. The expression of miR-17 was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The miR-17-targeting gene phosphatase and tensin homolog (PTEN) was predicted using bioinformatics and its expression was evaluated with RT-qPCR and western blot analysis. Endometrial cells were isolated from patients with AM and healthy controls. They were cultured in vitro and transfected with antagomiR-17 to downregulate miR-17 expression, subsequently cell viability and apoptosis were measured using MTT and flow cytometry. The expression of PTEN and cell cycle-and apoptosis-related proteins were evaluated using western blot analysis. Endometrial cells that stably overexpressed PTEN were screened in vitro by co-culture with G418. A dual-luciferase reporter assay was conducted to verify whether miR-17 was directly bound to PTEN mRNA. The results demonstrated that expression of miR-17 was significantly increased in the endometrial tissues of patients with AM compared with control patients (P<0.05). PTEN mRNA and protein expression were significantly lower in the AM group compared with the control group (P<0.05). When the expression of miR-17 in the cells was downregulated, the expression of PTEN was significantly increased (P<0.05). In addition, expression of Bcl-2 protein was significantly decreased and that of Bax protein significantly increased compared with the negative control (both P<0.05). The expression of cyclins E1 and D1 were also significantly downregulated (P<0.05). When PTEN was overexpressed or miR-17 was downregulated, the viability of endometrial cells significantly decreased and cell apoptosis significantly increased (all P<0.05). A dual-luciferase reporter assay indicated that miR-17 could directly bind to the PTEN mRNA 3'-untranslated region to regulate its expression. Thus the current study indicates that expression of miR-17 was increased in the endometrial tissues of patients with AM and may influence cell apoptosis and cyclin expression through the targeted regulation of PTEN. These results suggest that miR-17 promotes the occurrence and development of AM.

show abstract

“…Nevertheless, nanocompartments have unique advantages due to their intrinsic architecture, hollow spheres with hydrophilic cavities surrounded by a membra-nous structure possessing hydrophobic cores. They enable the efficient loading of various hydrophilic and hydrophobic therapeutic agents ranging from small molecular weight drugs to DNA and RNA for drug delivery, [17][18][19][20][21] nanoparticles for catalytic properties, 22,23 and various enzymes for the development of artificial organelles 24 functional in vivo. 25 While both liposomes and polymersomes allow tailoring for biocompatibility, stimuli-responsiveness and biodegradability, polymersomes are an improved alternative as they exhibit higher mechanical stability compared to their counterpart, liposomes.…”

Section: Introductionmentioning

confidence: 99%